Boruzu Injection
Product Images NDC 70121-2484

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Boruzu (NDC 70121-2484). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amneal Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Boruzu Bortezomib Injection 1)

FDA Label Image

1 (Boruzu Bortezomib Injection 10)

This text provides information about dilution for a medication to be administered via subcutaneous injection. It states that no further dilution is required and indicates the volume of the medication to be 2.1 mL, as well as the type of solution (0.9% Sodium Chloride Injection) to be used. The text appears to include instructions for achieving a specific concentration, although some characters are unclear.*

FDA Label Image

1 (Boruzu Bortezomib Injection 11)

This text provides instructions for the administration of Boruzu (bortezomib) injections, specifying "Subcutaneous Injection Only" and "Intravenous Injection Only" options. It also indicates the addition of 2.1 mL of 0.9% Sodium Chloride Injection without further dilution required. Stickers are recommended to be placed on the vial and syringe based on the administration route. For detailed instructions, it refers the reader to the Prescribing Information in Section 2.*

FDA Label Image

1 (Boruzu Bortezomib Injection 2)

FDA Label Image

1 (Boruzu Bortezomib Injection 3)

FDA Label Image

1 (Boruzu Bortezomib Injection 4)

This excerpt provides information about the proportion of patients under treatment with Bortezomib and Dexamethasone over a period of 480 days. The graph illustrates the number of patients remaining at various time points, highlighting a statistically significant difference (p < 0.0001) between the two treatment groups.*

FDA Label Image

1 (Boruzu Bortezomib Injection 5)

This is a data table showing the proportion of patients over time who remained on Bortezomib and Dexamethasone treatment. The table presents the number of patients remaining at each time point, along with the p-value from the log-rank test. The data suggests a comparison between the two treatments based on patient retention rates.*

FDA Label Image

1 (Boruzu Bortezomib Injection 6)

This text contains information related to a study or analysis involving the use of different treatments or interventions (B-CAP and R-CHOP) on subjects at risk. The results are presented in a table or graph format showing data points over varying time intervals (0 to 42 months). The statistical analysis included a log-rank test, with a p-value of less than 0.001 indicating potential significance. The specific outcomes or variables being measured are not clearly stated in the provided text.*

FDA Label Image

1 (Boruzu Bortezomib Injection 7)

This text contains survival data showing that 100% of subjects were alive at various time points following randomization in two treatment groups (BR-CAP and R-CHOP). The hazard ratio for survival between the two groups was 0.66 (95% CI: 0.51, 0.85). The data includes the number of subjects at risk for each time point up to 108 months. The study followed subjects for a span of 108 months, with the number of subjects at risk decreasing over time in both groups.*

FDA Label Image

1 (Boruzu Bortezomib Injection 8)

FDA Label Image

1 (Boruzu Bortezomib Injection 9)

This text contains information about a medication named BORUZU (bortezomib injection) prescribed for intravenous or subcutaneous use. It includes details on dosage, dilution instructions, storage conditions, and a warning about handling hazardous drugs. The medication is available as a single-dose vial and should be discarded if any portion is left unused. The manufacturer is Amneal Oncology Pvt. Ltd., and the distributor is Amneal Pharmaceuticals LLC. The medication contains 2.5 mg of bortezomib per mL, along with mannitol, sodium chloride, and water for injection. The text also provides the NDC (National Drug Code) number for the medication.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.